^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    beroterkib anhydrous (ASTX029)

    i
    Company:
    Otsuka
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    Apply
    A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia (NCT06113289)
    Phase 1/2
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    02/12/2025
    Initiation :
    02/08/2024
    Primary completion :
    05/01/2027
    Completion :
    05/01/2029
    KRAS • NF1 • PTPN11
    |
    Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)